4 Healthcare Stock Stories Making Sector Headlines Thursday

Celgene Corp. (NASDAQ:CELG): Closing price $145.59

Celgene Corp.’s wholly-owned subsidiary Celgene International Sàrl, announced Thursday that updated results from MM-003, a phase III multi-center, randomized open-label study of pomalidomide (marketed as POMALYST in the United States and IMNOVID in the European Union) plus low-dose dexamethasone, were published online prior to print in The Lancet Oncology. The evaluation compared oral pomalidomide plus low-dose dexamethasone with high-dose dexamethasone in patients suffering from refractory or relapsed and refractory multiple myeloma, who have failed a minimum of two prior therapies with both bortezomib and lenalidomide, administered alone or in combination.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CELG-20130905

Boston Scientific Corp. (NYSE:BSX): Closing price $11.57

Data published online in a key medical journal The Journal of Allergy and Clinical Immunology indicate a breakthrough in Boston Scientific tech for the treatment of severe asthma that has been shown to be safe and effective over a minimum of five years. The official scientific journal of the American Academy of Allergy, Asthma & Immunology and the most-cited journal in the field of allergy and clinical immunology, featured data from the Asthma Intervention Research 2 clinical trial studying the safety and effectiveness of the Boston Scientific AlaicBronchial Thermoplasty System. These long-term data are based on a post-approval study of BT-treated patients from the AIR2 Trial who were monitored for five years.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BSX-20130905

Neuralstem, Inc. (AMEX:CUR): Closing price $1.66

On Thursday, Neuralstem announced that it has entered into arrangements with certain accredited investors for a registered direct placement of 2.535 million shares of common stock at a price of $1.60 apiece for total gross proceeds of $4.056 million. Further, the firm will issue to each investor a warrant to buy a number of shares of common stock equal to 50 percent of the number of shares bought by the investor in the offering. The warrants have an exercise price of $2 per share, and are exercisable six months from issuance date and for a term of 5 years from the initial exercise date. The offering should close on or about September 9, subject to satisfaction of the usual closing conditions.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CUR-20130905

Endo Health Solutions Inc. (NASDAQ:ENDP): Closing price $43.05

Endo Health’s subsidiary Endo Pharmaceuticals Inc. said Thursday that the FDA has accepted for review the complete response submission made by Endo to the new drug application for its long-acting testosterone undecanoate injection, Aveed, intended for men diagnosed with hypogonadism. In conjunction with the acceptance, the FDA assigned Endo’s NDA a new prescription drug user fee Act action date of Feb. 28, 2014.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ENDP-20130905

Don’t Miss: Here’s Why States Want to Avoid the Word “Obamacare”.

 

More from The Cheat Sheet